Public Release: 

PPMD awards $600,000 to NJIT and Talem for Duchenne muscular dystrophy exoskeleton

New grant to help increase range of motion for individuals living with loss of muscle function

New Jersey Institute of Technology

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $600,000 grant to be awarded to the New Jersey Institute of Technology (NJIT) and Talem Technologies (Talem) as part of the organization's ongoing exploration of robotic technology to assist people living with Duchenne. PPMD is funding a two-year study to incorporate NJIT's technology - an embedded computer, software, a force sensor and a motor - as an add-on to an existing passive, spring-loaded device developed by Talem Technologies founder Blake Mathie as a zero-gravity support for people with Duchenne.

Duchenne muscular dystrophy is the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in every 5,000 live male births. PPMD has been an early funder of several robotic programs that strive to improve the quality of life for people with Duchenne. Robotic technology is about building strength in a disease that robs people of the ability to perform everyday tasks that most of us take for granted.

The Exoskeleton

The upper-extremity exoskeleton developed by Detroit-based Talem Technologies will be further refined in collaboration with biomedical engineers at NJIT to accept the university's modular robotic assistance technology. The device would be the first of its kind to provide intuitive robotic guidance controls and motorized assistance to people with Duchenne, allowing them to continue to use their arms as their muscles weaken.

Starting this week, the study leaders - Dr. Richard Foulds and Madeline Corrigan from NJIT and Blake Mathie from Talem Technologies - will begin recruiting up to 30 non-ambulatory participants living with Duchenne from across the country to use the device and report back regularly on their experiences incorporating it into their daily lives.

People with Duchenne lack the protein dystrophin, which acts as both the glue that holds muscles together and a shock absorber that allows them to contract and relax without being damaged. Without dystrophin, their muscles are not able to repair themselves from the tiny tears that occur on a daily basis with normal usage. People with Duchenne progressively lose strength, making it increasingly difficult to walk and to lift objects.

PPMD provided Talem Technologies a similar grant in 2015 that allowed Talem the ability to first test the X-Ar passive arm support with patients. This newest grant was a natural next step in the formation of promising exoskeleton technology, according to PPMD's founding president and CEO, Pat Furlong.

"PPMD has always supported innovation. We are thrilled that the teams at NJIT and Talem Technologies have come together to further enhance this exciting device. They have listened to patients and continue to make updates. We believe this exoskeleton technology has the ability to spare muscle deterioration keeping people with Duchenne stronger for longer and has the potential to assist everyone living with Duchenne," says Furlong.

Furlong continues, "PPMD's robust research pipeline will continue to focus on new and leading therapeutics that carry with them the potential to end Duchenne. But we need to simultaneously support innovative technology that will maintain muscle strength and ultimately independence. We believe that the technology being developed under this project is an example of that kind of innovation."

NJIT's technology uses what is known as admittance control, a robotic control paradigm in which the motion of the robot is controlled by the magnitude and direction of the forced applied by the user's arm. Compared to passive arm supports that require the user to have sufficient strength to move them, admittance controlled devices significantly minimize friction and inertia and provide more precise compensation against gravity, reducing the exertion necessary to move a limb, particularly vertically.

Participants in the study will receive a pair of wheelchair-mountable passive arm supports to be used regularly inside their homes, as well as in classrooms, workplaces and other community settings. After a few months, each participant will receive a modular upgrade to partially motorize their arm support.

"We will start with the passive device and then seamlessly add vertical assistance as an initial step - our studies show this is often the first degree of freedom to be limited in the case of progressive diseases - operated by force sensor, embedded computer and motor," said Foulds, co-director of NJIT's Rehabilitation Engineering Research Center and the principal investigator of the study.

Mathie called modularity a core principle of the device, which Talem plans to commercialize. "Not everyone needs a car with all the bells and whistles, nor a barebones model. What they need today may not be what they need tomorrow and so we are developing this device to serve the widest population possible, adding assistance as it is needed," he says, adding, "Wheelchairs provide freedom for people who have lost the use of their legs to go where they want, but they don't give them the independence to do what they want once they get there. This technology is designed to give them that independence."

The Team

NJIT and Talem Technologies met in April 2015 at a meeting convened by PPMD for Duchenne stakeholders from around the world to discuss the robotic technology and the potential it holds for the community. PPMD - together with UPPMD - gathered the best and brightest robotics experts and engineers who were working at the time to apply their innovations to Duchenne.

Madeline Corrigan, a doctoral candidate in biomedical engineering and co-principal investigator of the study, enrolled at NJIT with the express purpose of creating devices to help individuals with muscular dystrophy. "Based on my personal connection to the Duchenne community, I was committed to developing assistive technology that would provide a greater degree of independence for these individuals," she says. After working with Foulds on an early prototype using a fully motorized, wheelchair-mountable reaching and grasping robot, the two established a novel approach to upper extremity exoskeleton design: motorization of commercially available passive arm supports using admittance control.

"By implementing modular upgrades to a passive arm support, we can provide the user with assistance as needed, based on their capabilities. And, as is especially important for individuals with Duchenne, we can increase the amount of assistance as the user's capabilities change over time," she noted.

Zachary Smith, the first person with Duchenne to use the device, leapt at the chance to try it and has now become an integral part of the study. "Eating started to become challenging and I was struggling to brush my hair and teeth - the basic stuff people can do. I knew I was losing my arm strength and it scared me because I had already lost the ability to use my legs," he recounts. "So I got on my computer, started searching for exoskeletons, and e-mailed a company developing the technology. I thought that if it were used in factories to reduce workers' muscle fatigue, why not on a wheelchair."

Four years later, he is now the dissemination consultant for the NJIT/Talem project, responsible for outreach with participants, responding to their concerns and questions via Skype from his Florida home.

His own goal, Smith says, is to retain his arm strength as long as possible, "I want to be more independent. Rather than asking my parents and sister I want to do more things on my own," says Smith, noting that he is now able to play fetch with his dog and ping pong with his grandfather. "But I also want to show other people that just because you have a disease doesn't mean you can't do things," he says. "People should preserve this ability as long as they can. I want to show them they can help themselves."

###

To learn more about recruitment criteria for this project, please visit the project website at https://centers.njit.edu/ppmd.

To learn more about PPMD's robotics initiative, please visit the website.

About Parent Project Muscular Dystrophy

Duchenne is a fatal genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy--our mission is to end Duchenne.

We invest deeply in treatments for this generation of people affected by Duchenne and in research that will benefit future generations. We advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. We demand optimal care, and we strengthen, unite and educate the global Duchenne community.

Everything we do--and everything we have done since our founding in 1994--helps people with Duchenne live longer, stronger lives. We will not rest until every person has a treatment to end Duchenne. Go to http://www.ParentProjectMD.org for more information or to learn how you can support our efforts and help families affected by Duchenne. Follow PPMD on Facebook, Twitter, and YouTube.

About New Jersey Institute of Technology

One of the nation's leading public technological universities, New Jersey Institute of Technology (NJIT) is a top-tier research university that prepares students to become leaders in the technology-dependent economy of the 21st century. NJIT's multidisciplinary curriculum and computing-intensive approach to education provide technological proficiency, business acumen and leadership skills. With an enrollment of 11,400 graduate and undergraduate students, NJIT offers small-campus intimacy with the resources of a major public research university. NJIT is a global leader in such fields as solar research, nanotechnology, resilient design, tissue engineering, and cybersecurity, in addition to others. NJIT ranks 5th among U.S. polytechnic universities in research expenditures, topping $121 million, and is among the top 1 percent of public colleges and universities in return on educational investment, according to PayScale.com. NJIT has a $1.74 billion annual economic impact on the State of New Jersey.

About Talem Technologies

Talem Technologies is a company built on overcoming challenges, defined by unparalleled achievements and empowered by unlimited opportunities. It's only natural that we'd put our roots down in Detroit - the birthplace of engineering innovation - a city whose people and goals mirror our own.

Our dream was set in motion by the X-Ar, an exoskeletal device that attaches to one's arm and works as a strength and control amplifier by providing dynamic support throughout a natural range of motion. The success of this achievement laid the entire foundation for a legacy of promise to our customers.

Each day, a talented team of thought leaders from industry, medicine, and academia dedicate themselves to the notion that the best solutions are elegant in their simplicity. They strive to find answers that are both lasting in function and quality, and designed to remain within reach of those who need them most.

The words "Empower the persistent to succeed" defines Talem Technologies' core philosophy and proudly positions the products we bring to market. These words drive us to keep moving toward the future and beyond. This is what we do. This is who we are.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.